Skip to main content

Increasing Detection and Improving Outcomes in Hereditary Transthyretin Amyloid Cardiomyopathy

Tracking # 20-1354258

Free

There are no ratings for this course

Learn more
Educator I3 HEALTH
CE Broker Reporting Reported automatically
Method Computer-Based Training

Course overview

Discover the latest advances in diagnosing and treating hereditary ATTR amyloidosis with cardiomyopathy (ATTR-CM) in this essential on-demand course. Gain practical strategies for early detection, explore emerging therapies, and review real-world patient cases. Learn to recognize key clinical features, navigate genetic testing, and optimize treatment decisions for this now-treatable disease. Enroll today to improve patient outcomes.

Subject areas

This course counts toward the state boards and subject areas below.

Arkansas State Board of Nursing

Certified Nurse Practitioner

1h Practice-Focused Continuing Education

Clinical Nurse Specialist

1h Practice-Focused Continuing Education

Licensed Practical Nurse

1h Practice-Focused Continuing Education

Registered Nurse

1h Practice-Focused Continuing Education

Registered Nurse Practitioner

1h Practice-Focused Continuing Education

District of Columbia Board of Nursing

Clinical Nurse Specialist

1h Relevant to Clinical Nurse Specialty

Licensed Practical Nurse

1h Licensed Practical Nurse - Continuing Education

Nurse Practitioner

1h Pharmacology Component

Registered Nurse

1h Registered Nurse District of Columbia - Continuing Education

Florida Board of Nursing - Certified Nursing Assistants

Certified Nursing Assistant

1h General

Georgia Board of Nursing

Licensed Practical Nurse

1h General

Registered Professional Nurse

1h General

Kansas State Board of Nursing

Clinical Nurse Specialist

1h Approved CNE Related to the Advanced Practice Registered Nurse

Licensed Practical Nurse

1h Continuing Nursing Education (CNE)

Nurse Practitioner

1h Approved CNE Related to the Advanced Practice Registered Nurse

Registered Nurse

1h Continuing Nursing Education (CNE)

New Hampshire Board of Nursing

Advanced Practice Registered Nurse

1h General CE

Licensed Practical Nurse

1h General CE

Registered Nurse

1h General CE

New Mexico Board of Nursing

Certified Nurse Practitioner

1h Continuing education relevant to nursing practice

Clinical Nurse Specialist

1h Continuing education relevant to nursing practice

Licensed Practical Nurse

1h Continuing education relevant to the licensed practical nurse

Registered Nurse

1h Continuing education relevant to nursing practice

North Dakota Board of Nursing

Advanced Practice Registered Nurse

1h CE Related to Nursing Practice

Licensed Practical Nurse

1h CE Related to Nursing Practice

Registered Nurse

1h CE Related to Nursing Practice

South Carolina Board of Nursing

Advanced Practice Registered Nurse

1h General

Licensed Practical Nurse

1h General

Registered Nurse

1h General

Tennessee Board of Nursing

Advanced Practice Registered Nurse

1h General

Licensed Practical Nurse

1h General

Registered Nurse

1h General

Wyoming Board of Nursing

Certified Nurse Midwife

1h General

Certified Nurse Practitioner

1h General

Certified Nurse Specialist

1h General

Certified Nursing Assistant

1h General

Licensed Practical Nurse

1h General

Registered Nurse

1h General

Disclosure statements

DISCLOSURE OF RELEVANT FINANCIAL INFORMATION WITH INELIGIBLE COMPANIES

i3 Health endorses the standards of the ACCME, ANCC, and ACPE that require everyone in a position to control the content of a CME/NCPD/CPE activity to disclose all financial relationships with ineligible companies that are related to the content of the CME/NCPD/CPE activity. CME/NCPD/CPE activities must be balanced, independent of commercial bias, and promote improvements or quality in healthcare. All recommendations involving clinical medicine must be based on evidence accepted within the medical profession.

A conflict of interest is created when an individual has an opportunity to affect CME/NCPD/CPE content about products or services of an ineligible company with which he/she has a financial relationship, which therefore may bias their opinions and teaching. This may include receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, stocks, or other financial benefits.

i3 Health will identify, review, and mitigate all relevant financial relationships that speakers, authors, or planners disclose prior to an educational activity being delivered to learners. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation. i3 Health does not endorse any products or services.

Relevant financial relationships exist between the following individuals and ineligible companies:

Mathew Maurer, MD, discloses that he has served on an advisory board or panel for Alnylam, Attralus, BridgeBio, Intellia, Ionis, and Pfizer; and that he has received grants/research support from Alnylam, Attralus, BridgeBio, Intellia, Ionis, and Pfizer. 

The i3 Health planners, reviewers, and managers have nothing to disclose.

i3 Health has mitigated all relevant financial relationships.